Lucas GEYER

Dr. Lucas GEYER


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LGLucas GEYER
Lucas GEYER
WTWOLF Thibaut
WOLF Thibaut
MCMarie-Pierre Chenard
Marie-Pierre Chenard
HCHélène Cebula
Hélène Cebula
RSRoland Schott
Roland Schott
BLBenoit Lhermitte
Benoit Lhermitte
CDKN2A is a tumor suppressor gene encoding the p16 protein, a key regulator of the cell cycle. CDKN2A homozygous deletion is a central prognostic factor for numerous tumors and can be detected by several techniques. This study aims to evaluate the extent to which immunohistochemical levels of p16 expression may provide information about CDKN2A deletion. A retrospective study was conducted in 173 gliomas of all types, using p16 IHC and CDKN2A fluorescent in situ hybridization. Survival analyses were performed to assess the prognostic impact of p16 expression and CDKN2A deletion on patient outcomes. Three patterns of p16 expression were observed: absence of expression, focal expression, and overexpression. Absence of p16 expression was correlated with worse outcomes. p16 overexpression was associated with better prognoses in MAPK-induced tumors, but with worse survival in IDH-wt glioblastomas. CDKN2A homozygous deletion predicted worse outcomes in the overall patient population, particularly in IDH-mutant 1p/19q oligodendrogliomas (grade 3). Finally, we observed a significant correlation between p16 immunohistochemical loss of expression and CDKN2A homozygosity. IHC has strong sensitivity and high negative predictive value, suggesting that p16 IHC might be a pertinent test to detect cases most likely harboring CDKN2A homozygous deletion.

3 November 2026 in International Journal of Surgery Case Reports
Verified
Journal Article
Open access
PKPierre Klienkoff
Pierre Klienkoff
AKAron Khemis
Aron Khemis
TDThibault Dedieu
Thibault Dedieu
WTWOLF Thibaut
WOLF Thibaut
SBSophie Bahi-Gross
Sophie Bahi-Gross
LGLucas GEYER
Lucas GEYER
Introduction: Oral potentially malignant disorders (OPMDs), including leukoplakia and oral lichen planus, carry an increased risk of malignant transformation to oral squamous cell carcinoma, with reported rates of 6.64–9.5% for leukoplakia and 0.7–1.4% for lichen planus. Current decision trees recommend excision whenever feasible and do not stratify non-dysplastic lesions by risk factors, nor do they address whether the coexistence of multiple OPMDs should itself lower the threshold for intervention. Case presentation: This report describes the case of a 73-year-old man with pre-existing oral lichen planus who developed a new, non-dysplastic leukoplakic plaque on the lateral border of the tongue. Despite the absence of dysplasia on initial biopsy, the lesion was excised in light of the lesion’s high-risk features and the patient’s coexisting OPMDs. Histopathology of the excised specimen unexpectedly revealed an in situ squamous cell carcinoma; re-excision by partial glossectomy showed no residual carcinoma, with no recurrence at 2-year follow-up. Discussion: Prompted by this case, the coexistence of multiple OPMDs is proposed as a candidate risk factor (hypothesis) that could be incorporated into the leukoplakia management algorithm, supplementing existing decision trees with a branch that stratifies non-dysplastic lesions by risk factors. Conclusion: This case-based framework is intended to be hypothesis-generating and warrants validation in larger cohorts.